Mycophenolate

Manufactured by Genentech

Mycophenolate is a lab equipment product used for immunosuppression. It is a chemical compound that inhibits the enzyme inosine monophosphate dehydrogenase, which is essential for the de novo synthesis of guanine nucleotides. This mechanism of action leads to the inhibition of lymphocyte proliferation.

Automatically generated - may contain errors

Lab products found in correlation

Methylprednisolone, by Pfizer (3 mentions) Cobra venom factor, by Merck Group (1 mentions)

3 protocols using mycophenolate

Xenogeneic Lung Transplant Immunosuppression

Cited 2 times

Check if the same lab product or an alternative is used in the 5 most similar protocols

To minimize the risk of rejection, an immunosuppression regimen informed by current practices in clinical transplantation, and described for use in xeno-support of human lungs, was used (Figure 1B).^{14 ,15 (link)} At 4 hours before cross-circulation, xeno-support swine were anesthetized, intubated, and administered cobra venom factor (1 mg; Sigma-Aldrich) to deplete complement activity.^{16 (link)} Intravenous diphenhydramine (50 mg; West Ward) and methylprednisolone (1 g; Pfizer) were administered to limit the inflammatory response associated with cobra venom factor. Intravenous tacrolimus (5 mg; Astellas) and mycophenolate (500 mg; Genentech) were also administered before reperfusion and redosed every 12 hours (Supplemental Figure S1C, http://links.lww.com/HEP/F706). methylprednisolone (125 mg; Pfizer) was readministered every 8 hours after the initial dosage.

Wu W.K., Ukita R., Patel Y.J., Cortelli M., Trinh V.Q., Ziogas I.A., Francois S.A., Mentz M., Cardwell N.L., Talackine J.R., Grogan W.M., Stokes J.W., Lee Y.A., Kim J., Alexopoulos S.P, & Bacchetta M. (2023). Xenogeneic cross-circulation for physiological support and recovery of ex vivo human livers. Hepatology (Baltimore, Md.), 78(3), 820-834.

+ Open protocol

+ Expand

Immunosuppressive Regimen for Xenotransplantation

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

To minimize the risk of rejection, an immunosuppression regimen informed by current practices in clinical transplantation, and previously described for use in xeno-support of human lungs, was used (Fig. 1b).^{14 ,15 (link)} At 4 h before cross-circulation, xeno-support swine were anesthetized, intubated and administered cobra venom factor (CVF, 1 mg; Sigma-Aldrich) to deplete complement activity.¹⁶ Intravenous diphenhydramine (50 mg; West-Ward) and methylprednisolone (1 g; Pfizer) were administered to limit the inflammatory response associated with CVF. Intravenous tacrolimus (5 mg; Astellas) and mycophenolate (500 mg; Genentech) were also administered prior to reperfusion and re-dosed every 12 hours (Fig. S1c). methylprednisolone (125 mg; Pfizer) was re-administered every 8 hours after the initial dose.

Pickering D.S., Taverna F.A., Salter M.W, & Hampson D.R. (1995). Palmitoylation of the GluR6 kainate receptor.. Proceedings of the National Academy of Sciences of the United States of America, 92(26), 12090-12094.

+ Open protocol

+ Expand

Xenogeneic Lung Transplant Immunosuppression

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

To minimize the risk of immunologic rejection, an immunosuppression regimen informed by established protocols and current practices in clinical lung transplantation was used (Fig. 1B). Four hours before initiation of xenogeneic XC, xeno-support swine were anesthetized, intubated, and administered CVF (1 mg; Sigma-Aldrich) to deplete complement activity (61 (link), 62 (link)). Intravenous diphenhydramine (50 mg; West-Ward Pharmaceuticals) and methylprednisolone (1 g; Pfizer) were administered to mitigate hemodynamic instability occasionally associated with CVF. Intravenous tacrolimus (5 mg; Astellas) and mycophenolate (500 mg; Genentech) were also administered before reperfusion and redosed every 12 hours. methylprednisolone (125 mg; Pfizer) was readministered every 8 hours after the initial dose.

Wu W.K., Stier M.T., Stokes J.W., Ukita R., Patel Y.J., Cortelli M., Landstreet S.R., Talackine J.R., Cardwell N.L., Simonds E.M., Mentz M., Lowe C., Benson C., Demarest C.T., Alexopoulos S.P., Shaver C.M, & Bacchetta M. (2023). Immune characterization of a xenogeneic human lung cross-circulation support system. Science Advances, 9(13), eade7647.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!